Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts

Published:2010-09 Issue:9 Volume:34 Page:1214-1223
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Lim Wah-Seng,Tardi Paul G.,Dos Santos Nancy,Xie Xiaowei,Fan Mannie,Liboiron Barry D.,Huang Xiaoping,Harasym Troy O.,Bermudes David,Mayer Lawrence D.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference38 articles.

1. Drug therapy for acute myeloid leukemia;Tallman;Blood,2005

2. The role of anthracyclines in adult acute lymphoblastic leukaemia;Bassan;Leukemia,1996

3. Optimal management of adults with ALL;Rowe;Br J Haematol,2009

4. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy;Tardi;Leuk Res,2009

5. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice;Mayer;Mol Cancer Ther,2006

Cited by 134 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia;Small;2024-06-27

2. Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data;Leukemia & Lymphoma;2024-06-11

3. Transplant Eligible and Ineligible Elderly Patients with AML—A Genomic Approach and Next Generation Questions;Biomedicines;2024-04-29

4. CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis;Blood;2024-04-18

5. Advancing Bone-Targeted Drug Delivery: Leveraging Biological Factors and Nanoparticle Designs to Improve Therapeutic Efficacy;ACS Biomaterials Science & Engineering;2024-03-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3